No Data
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone's Innovative Therapies Gain Recognition
NurExone's ExoPTEN, Loaded With SiRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
Updates From NurExone: Growth Conference Presentation and Website Relaunch
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
No Data
